AI Article Synopsis

  • Pulmonary metastasis is a common recurrence of hepatocellular carcinoma (HCC), and this study analyzed the surgical outcomes of pulmonary metastasectomy in 20 patients from 1990 to 2007 to assess survival rates and prognostic factors.
  • The 5-year overall survival rate was 46.9%, while the cancer-specific survival rate was 63.2%, with a significant impact from preoperative alpha-fetoprotein (AFP) levels; higher levels (≥500 ng/ml) were linked to worse survival outcomes.
  • The findings suggest that serum AFP levels could be important predictors for the success of pulmonary metastasectomy in HCC patients.

Article Abstract

Purpose: Pulmonary metastasis is the most common type of extrahepatic recurrence of hepatocellular carcinoma (HCC). The outcome of pulmonary metastasectomy of HCC has not yet been thoroughly investigated. The outcomes of surgical treatment of pulmonary metastases from HCC were reviewed in order to analyze the postoperative survival and the relevant prognostic factors.

Methods: This study retrospectively reviewed 20 patients who underwent pulmonary metastasectomy from an HCC between 1990 and 2007 at two institutions. The surgical outcome was evaluated by both the overall survival and cancer-specific survival after pulmonary resection. The association between various clinico-pathological factors and the survival outcome was analyzed.

Results: The overall survival rate after the initial pulmonary metastasectomy was 46.9% at 5 years, and the cancer-specific 5-year survival rate was 63.2%. One patient died of surgery-related events 19 days after the pulmonary resection. The preoperative AFP (alpha-fetoprotein) level was found to be a significant prognostic factor for both overall and cancer-specific survival for patients undergoing pulmonary metastasectomy. Both the overall and cancer-specific survival rates were significantly worse for the patients with AFP ≥ 500 ng/ml in comparison to those with AFP < 500 ng/ml (p < 0.05). No other factors were associated with the survival after pulmonary metastasectomy.

Conclusion: The serum level of AFP might be a valuable predictor for the outcome of pulmonary metastasectomy required for metastasis of HCC.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00595-011-0090-8DOI Listing

Publication Analysis

Top Keywords

pulmonary metastasectomy
16
cancer-specific survival
12
pulmonary
9
pulmonary metastasis
8
hepatocellular carcinoma
8
alpha-fetoprotein level
8
metastasectomy hcc
8
survival
8
pulmonary resection
8
survival rate
8

Similar Publications

This meta-analysis aimed to compare the outcomes of video-assisted thoracic surgery (VATS) and open thoracotomy in pediatric patients undergoing pulmonary metastasectomy for various malignancies. We systematically searched PubMed, Embase, and Cochrane Library databases for studies comparing VATS and open thoracotomy in pediatric patients. The treatment effects for continuous outcomes were compared using mean differences (MDs), and binary endpoints were evaluated using odds ratios (ORs), with 95% confidence intervals (CIs).

View Article and Find Full Text PDF

We would like to express our sincere gratitude for the thoughtful reflections on our recent study regarding pulmonary metastasectomy, and we greatly appreciate the constructive dialog that our work has sparked [...

View Article and Find Full Text PDF

Recent studies report excellent local control (LC) and favorable toxicities of stereotactic ablative radiotherapy (SABR) for pulmonary metastasis (PM) from sarcoma. This study compared the LC and survival of SABR and metastasectomy for sarcoma PM. We analyzed the LC rates of 54 PMs treated with SABR between 2008 and 2022.

View Article and Find Full Text PDF

Background And Objectives: Due to heterogeneous characteristics of primary cancers, the efficacy of pulmonary metastasectomy (PM) in nonprimary lung cancers has not been investigated. This study aims to investigate the clinical outcomes of PM for non-primary lung cancer.

Methods: A systematic search for meta-analyses on PM for nonprimary lung cancers was conducted, encompassing publications up to January 3, 2024.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!